title: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
abstract: OBJECTIVE
  To compare the survival benefit obtained with cisplatin plus gemcitabine, a cisplatin-based triplet, and nonplatinum sequential doublets in advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Stage IIIB to IV NSCLC patients were randomly assigned to receive cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8, every 3 weeks for six cycles (CG); cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8, every 3 weeks for six cycles (CGV); or gemcitabine 1,000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8, every 3 weeks for three cycles, followed by vinorelbine 30 mg/m2 days 1 and 8 plus ifosfamide 3 g/m2 day 1, every 3 weeks for three cycles (GV-VI).
  
  
  RESULTS
  Five hundred fifty-seven patients were assigned to treatment (182 CG, 188 CGV, 187 GV-VI). Response rates were significantly inferior for the nonplatinum sequential doublet (CG, 42%; CGV, 41%; GV-VI, 27%; CG v GV-VI, P =.003). No differences in median survival or time to progression were observed. Toxicity was higher for the triplet: grade 3 to 4 neutropenia (GC, 32%; CGV, 57%; GV-VI, 27%; P <.05); neutropenic fever (CG, 4%; CGV, 19%; GV-VI, 5%; P <.0001); grade 3 to 4 thrombocytopenia (CG, 19%; CGV, 23%; GV-VI, 3%; P =.0001); and grade 3 to 4 emesis (GC, 22%; GCV, 32%; GV-VI, 6%; P <.0001).
  
  
  CONCLUSIONS
  On the basis of these results, CG remains a standard regimen for first-line treatment of advanced NSCLC.
authors.affiliation: Hospital Arnau de Vilanova, San Clemente 12, 46015 Valencia, Spain. alberola_vicara@gva.es
authors.forename: V
authors.initials: V
authors.lastname: Alberola
authors.forename: C
authors.initials: C
authors.lastname: Camps
authors.forename: M
authors.initials: M
authors.lastname: Provencio
authors.forename: D
authors.initials: D
authors.lastname: Isla
authors.forename: R
authors.initials: R
authors.lastname: Rosell
authors.forename: C
authors.initials: C
authors.lastname: Vadell
authors.forename: I
authors.initials: I
authors.lastname: Bover
authors.forename: A
authors.initials: A
authors.lastname: Ruiz-Casado
authors.forename: P
authors.initials: P
authors.lastname: Azagra
authors.forename: U
authors.initials: U
authors.lastname: Jiménez
authors.forename: J L
authors.initials: JL
authors.lastname: González-Larriba
authors.forename: P
authors.initials: P
authors.lastname: Diz
authors.forename: F
authors.initials: F
authors.lastname: Cardenal
authors.forename: A
authors.initials: A
authors.lastname: Artal
authors.forename: A
authors.initials: A
authors.lastname: Carrato
authors.forename: S
authors.initials: S
authors.lastname: Morales
authors.forename: J J
authors.initials: JJ
authors.lastname: Sanchez
authors.forename: R
authors.initials: R
authors.lastname: de las Peñas
authors.forename: E
authors.initials: E
authors.lastname: Felip
authors.forename: G
authors.initials: G
authors.lastname: López-Vivanco
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013030:Spain; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine; D007069:Ifosfamide; D000093542:Gemcitabine